Deletion analysis of the p16 tumour suppressor gene in phaeochromocytomas

Ricardo C Aguiar, Patricia L Dahia, Heinz Sill, Sergio P A Toledo, John M. Goldman, Nicholas C P Cross

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Background and Objective. The molecular pathogenesis of phaeochromocytoma has not yet been fully established. The p16 tumour suppressor gene is often inactivated in a wide variety of primary human malignancies, including tumours of ectodermal origin. We have therefore examined the status of the p16 gene in a series of phaeochromocytomas. Design. We studied tumour and constitutive DNA from 26 phaeochromocytoma patients. Twenty-two cases were of sporadic tumours whereas four patients had a hereditary form of the disease. Four tumours were malignant. We performed a semiquantitative multiplex PCR in which the p16 gene was coamplified with an unrelated sequence as an internal control. Standards were constructed by mixing DNA from cell lines with a known pig status to simulate various degrees of p 16 loss. Deletion of the p16 gene was determined by densitometry, measuring the ratio of intensity of the two resulting bands as an indication of the relative abundance of the two templates in the sample. Results. No homozygous deletion of the p16 tumour suppressor gene was found in any of the phaeochromocytoma samples. Conclusions. We have demonstrated that the p16 gene is not deleted in sporadic, hereditary, malignant or benign forms of phaeochromocytomas, and therefore probably does not play a role in the pathogenesis of this tumour. However, because of the small number of malignant cases analysed, we cannot exclude a low frequency of p16 deletions in this subset of tumours.

Original languageEnglish (US)
Pages (from-to)93-96
Number of pages4
JournalClinical Endocrinology
Volume45
Issue number1
DOIs
StatePublished - 1996
Externally publishedYes

Fingerprint

Pheochromocytoma
Tumor Suppressor Genes
p16 Genes
Neoplasms
Inborn Genetic Diseases
Densitometry
Multiplex Polymerase Chain Reaction
DNA
Swine
Cell Line

ASJC Scopus subject areas

  • Endocrinology

Cite this

Deletion analysis of the p16 tumour suppressor gene in phaeochromocytomas. / Aguiar, Ricardo C; Dahia, Patricia L; Sill, Heinz; Toledo, Sergio P A; Goldman, John M.; Cross, Nicholas C P.

In: Clinical Endocrinology, Vol. 45, No. 1, 1996, p. 93-96.

Research output: Contribution to journalArticle

Aguiar, Ricardo C ; Dahia, Patricia L ; Sill, Heinz ; Toledo, Sergio P A ; Goldman, John M. ; Cross, Nicholas C P. / Deletion analysis of the p16 tumour suppressor gene in phaeochromocytomas. In: Clinical Endocrinology. 1996 ; Vol. 45, No. 1. pp. 93-96.
@article{dafea7c6ec92435eab10d352712404ea,
title = "Deletion analysis of the p16 tumour suppressor gene in phaeochromocytomas",
abstract = "Background and Objective. The molecular pathogenesis of phaeochromocytoma has not yet been fully established. The p16 tumour suppressor gene is often inactivated in a wide variety of primary human malignancies, including tumours of ectodermal origin. We have therefore examined the status of the p16 gene in a series of phaeochromocytomas. Design. We studied tumour and constitutive DNA from 26 phaeochromocytoma patients. Twenty-two cases were of sporadic tumours whereas four patients had a hereditary form of the disease. Four tumours were malignant. We performed a semiquantitative multiplex PCR in which the p16 gene was coamplified with an unrelated sequence as an internal control. Standards were constructed by mixing DNA from cell lines with a known pig status to simulate various degrees of p 16 loss. Deletion of the p16 gene was determined by densitometry, measuring the ratio of intensity of the two resulting bands as an indication of the relative abundance of the two templates in the sample. Results. No homozygous deletion of the p16 tumour suppressor gene was found in any of the phaeochromocytoma samples. Conclusions. We have demonstrated that the p16 gene is not deleted in sporadic, hereditary, malignant or benign forms of phaeochromocytomas, and therefore probably does not play a role in the pathogenesis of this tumour. However, because of the small number of malignant cases analysed, we cannot exclude a low frequency of p16 deletions in this subset of tumours.",
author = "Aguiar, {Ricardo C} and Dahia, {Patricia L} and Heinz Sill and Toledo, {Sergio P A} and Goldman, {John M.} and Cross, {Nicholas C P}",
year = "1996",
doi = "10.1111/j.1365-2265.1996.tb02065.x",
language = "English (US)",
volume = "45",
pages = "93--96",
journal = "Clinical Endocrinology",
issn = "0300-0664",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Deletion analysis of the p16 tumour suppressor gene in phaeochromocytomas

AU - Aguiar, Ricardo C

AU - Dahia, Patricia L

AU - Sill, Heinz

AU - Toledo, Sergio P A

AU - Goldman, John M.

AU - Cross, Nicholas C P

PY - 1996

Y1 - 1996

N2 - Background and Objective. The molecular pathogenesis of phaeochromocytoma has not yet been fully established. The p16 tumour suppressor gene is often inactivated in a wide variety of primary human malignancies, including tumours of ectodermal origin. We have therefore examined the status of the p16 gene in a series of phaeochromocytomas. Design. We studied tumour and constitutive DNA from 26 phaeochromocytoma patients. Twenty-two cases were of sporadic tumours whereas four patients had a hereditary form of the disease. Four tumours were malignant. We performed a semiquantitative multiplex PCR in which the p16 gene was coamplified with an unrelated sequence as an internal control. Standards were constructed by mixing DNA from cell lines with a known pig status to simulate various degrees of p 16 loss. Deletion of the p16 gene was determined by densitometry, measuring the ratio of intensity of the two resulting bands as an indication of the relative abundance of the two templates in the sample. Results. No homozygous deletion of the p16 tumour suppressor gene was found in any of the phaeochromocytoma samples. Conclusions. We have demonstrated that the p16 gene is not deleted in sporadic, hereditary, malignant or benign forms of phaeochromocytomas, and therefore probably does not play a role in the pathogenesis of this tumour. However, because of the small number of malignant cases analysed, we cannot exclude a low frequency of p16 deletions in this subset of tumours.

AB - Background and Objective. The molecular pathogenesis of phaeochromocytoma has not yet been fully established. The p16 tumour suppressor gene is often inactivated in a wide variety of primary human malignancies, including tumours of ectodermal origin. We have therefore examined the status of the p16 gene in a series of phaeochromocytomas. Design. We studied tumour and constitutive DNA from 26 phaeochromocytoma patients. Twenty-two cases were of sporadic tumours whereas four patients had a hereditary form of the disease. Four tumours were malignant. We performed a semiquantitative multiplex PCR in which the p16 gene was coamplified with an unrelated sequence as an internal control. Standards were constructed by mixing DNA from cell lines with a known pig status to simulate various degrees of p 16 loss. Deletion of the p16 gene was determined by densitometry, measuring the ratio of intensity of the two resulting bands as an indication of the relative abundance of the two templates in the sample. Results. No homozygous deletion of the p16 tumour suppressor gene was found in any of the phaeochromocytoma samples. Conclusions. We have demonstrated that the p16 gene is not deleted in sporadic, hereditary, malignant or benign forms of phaeochromocytomas, and therefore probably does not play a role in the pathogenesis of this tumour. However, because of the small number of malignant cases analysed, we cannot exclude a low frequency of p16 deletions in this subset of tumours.

UR - http://www.scopus.com/inward/record.url?scp=0029931446&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029931446&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2265.1996.tb02065.x

DO - 10.1111/j.1365-2265.1996.tb02065.x

M3 - Article

C2 - 8796144

AN - SCOPUS:0029931446

VL - 45

SP - 93

EP - 96

JO - Clinical Endocrinology

JF - Clinical Endocrinology

SN - 0300-0664

IS - 1

ER -